Boron determination in blood and tissue samples is a crucial task especially for treatment planning, preclinical research, and clinical application of boron neutron capture therapy (BNCT). Comparison of clinical findings remains difficult due to a variety of analytical methods, protocols, and standard reference materials in use. This paper addresses the comparability of inductively coupled plasma mass spectrometry, quantitative neutron capture radiography, and prompt gamma activation analysis for the determination of boron in biological samples. It was possible to demonstrate that three different methods relying on three different principles of sample preparation and boron detection can be validated against each other and yield consistent results for both blood and tissue samples. The samples were obtained during a clinical study for the application of BNCT for liver malignancies and therefore represent a realistic situation for boron analysis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00216-012-6329-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expression rate of LAT1 in high-grade parotid gland carcinoma and potential of BNCT as a treatment option for recurrent parotid gland carcinoma.
Appl Radiat Isot
January 2025
Department of Otolaryngology Head and Neck Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan; BNCT Joint Clinical Institute, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Purpose: Boron neutron capture therapy (BNCT) perform as a treatment option for locally advanced or recurrent unresectable head and neck cancers since June 2020 in Japan. The effect of BNCT on parotid carcinoma, which presents a variety of histologic types, remains unclear. The object of this study was to investigate the antitumor efficacy of BNCT against parotid gland carcinoma by focusing on LAT1, which is involved in the uptake of L-BPA, the boron compound used in BNCT.
View Article and Find Full Text PDFA 77-year-old man was referred to our department because of macrohematuria, oliguria, and a serum creatinine level of 2.47 mg/dL during boron neutron capture therapy (BNCT) for oropharyngeal cancer. At baseline, his creatinine level had been 0.
View Article and Find Full Text PDFFirst Observation of a Nuclear Recoil Peak at (100eV) with Crab: A Potential New Calibration Standard for Cryogenic Detectors.
J Low Temp Phys
December 2024
Physik-Department, Technische Universität München, Garching, Germany.
Any experiment aiming to measure rare events, like Coherent Elastic neutrino-Nucleus Scattering (CE NS) or hypothetical Dark Matter scattering, via nuclear recoils in cryogenic detectors relies crucially on a precise detector calibration at sub-keV energies. The Crab collaboration developed a new calibration technique based on the capture of thermal neutrons inside the target crystal. Together with the Nucleus experiment, first measurements with a moderated Cf neutron source and a cryogenic detector were taken.
View Article and Find Full Text PDFTranscriptome analysis of human oral squamous cancer SAS cells as an early response after boron neutron capture therapy.
Appl Radiat Isot
January 2025
Department of Molecular and Genomic Biomedicine, Nagasaki University Graduate School of Biomedical Sciences, 852-8523, Nagasaki, Japan; Central Radioisotope Division, National Cancer Center Research Institute, 104-0045, Tokyo, Japan; Division of BNCT, EPOC, National Cancer Center, Tokyo, Japan; Division of Chemotherapy and Clinical Cancer Research, National Cancer Center Research Institute, 104-0045, Tokyo, Japan. Electronic address:
Boron neutron capture therapy (BNCT) is based on nuclear reactions between thermal neutron and boron-10 preferentially distributed in the cancer cells. B-boronophenylalanine (BPA) is the approved drug for treatment of oral cancers for BNCT. However, the predictive biomarkers to evaluate therapeutic efficacy and side-effects have not been clarified yet.
View Article and Find Full Text PDFThe potential of the i-TED Compton camera array for real-time boron imaging and determination during treatments in Boron Neutron Capture Therapy.
Appl Radiat Isot
December 2024
Instituto de Física Corpuscular (CSIC-Universidad de Valencia), Valencia, Spain.
This paper explores the adaptation and application of i-TED Compton imagers for real-time dosimetry in Boron Neutron Capture Therapy (BNCT). The i-TED array, previously utilized in nuclear astrophysics experiments at CERN, is being optimized for detecting and imaging 478 keV gamma-rays, critical for accurate BNCT dosimetry. Detailed Monte Carlo simulations were used to optimize the i-TED detector configuration and enhance its performance in the challenging radiation environment typical of BNCT.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!